OnKure Therapeutics, Inc. (OKUR) Stock Forecast
OKUR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 6 analysts
- Price target
- $15.50 average of analyst targets
- Upside to target
- +638.1% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.35
- 52-week range
- $2.10 – $5.27
OKUR analyst ratings
6 analystsNumber of analysts at each rating.
OKUR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
OKUR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.41 | −$0.62 | −$0.29 | −$1.09 | +62.4% | 4 |
| Current fiscal year (2026) | −$1.83 | −$2.40 | −$1.47 | −$4.40 | +58.4% | 4 |
| Next fiscal year (2027) | −$1.53 | −$2.08 | −$1.15 | −$1.83 | +16.6% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
OKUR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $125,000 | $0 | $500,000 | 0.0% | 4 |
| Current fiscal year (2026) | $250,000 | $0 | $1.0M | 0.0% | 4 |
| Next fiscal year (2027) | $666,670 | $0 | $2.0M | +166.7% | 3 |
OKUR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
OKUR revenue: reported and forecast
OKUR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.57 | −$0.57 | −$0.57 | −$0.47 | −$0.41 | −28.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$2.50 | −$2.50 | −$2.50 | −$1.96 | −$1.83 | −26.9% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.13 | −$2.13 | −$2.13 | −$1.96 | −$1.53 | −28.3% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
OKUR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; OKUR beat in 6 of 8.
What analysts expect from OKUR
6 analysts cover OnKure Therapeutics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $15.50, 638.1% above the latest close of $2.10. Analysts expect earnings of −$1.83 per share for 2026, +58.4% from a year earlier. For 2027 the average estimate is −$1.53 per share on revenue of $0.7 million. OnKure Therapeutics beat the EPS estimate in 6 of the last 8 quarters.
Related: OKUR income statement, OKUR key metrics, OKUR chart. See the OKUR stock overview for the latest quote and news.
OKUR forecast FAQ
What is OnKure Therapeutics's price target?
The average analyst price target for OnKure Therapeutics is $15.50, 638.1% above the latest close of $2.10.
Is OnKure Therapeutics a buy, hold or sell?
Of 6 analysts covering OnKure Therapeutics, 5 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is OnKure Therapeutics's EPS forecast?
Analysts forecast −$1.83 per share for 2026 (range −$2.40 to −$1.47); for 2027 the estimate is −$1.53.
What is OnKure Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $0.2 million, growth of 0.0%; for 2027 it is $0.7 million.
When does OnKure Therapeutics report earnings?
OnKure Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.35.
Does OnKure Therapeutics usually beat earnings estimates?
OnKure Therapeutics reported EPS at or above the analyst estimate in 6 of the last 8 quarters.